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Abstract: Bronchopulmonary dysplasia (BPD) is the most common complication after preterm birth.
Pasteurized donor human milk (DHM) has increasingly become the standard of care for very preterm
infants over the use of preterm formula (PF) if the mother’s own milk (MOM) is unavailable. Studies
have reported beneficial effects of DHM on BPD. We conducted a systematic review and meta-analysis
of randomized controlled trials (RCTs) and observational studies on the effects of DHM on BPD and
other respiratory outcomes. Eighteen studies met the inclusion criteria. Meta-analysis of RCTs could
not demonstrate that supplementation of MOM with DHM reduced BPD when compared to PF
(three studies, risk ratio (RR) 0.89, 95% confidence interval (CI) 0.60–1.32). However, meta-analysis
of observational studies showed that DHM supplementation reduced BPD (8 studies, RR 0.78,
95% CI 0.67–0.90). An exclusive human milk diet reduced the risk of BPD, compared to a diet
with PF and/or bovine milk-based fortifier (three studies, RR 0.80, 95% CI 0.68–0.95). Feeding raw
MOM, compared to feeding pasteurized MOM, protected against BPD (two studies, RR 0.77, 95% CI
0.62–0.96). In conclusion, our data suggest that DHM protects against BPD in very preterm infants.
Keywords: donor human milk; bronchopulmonary dysplasia; breast milk; preterm
formula; pasteurization
1. Introduction
The nutritional and immunological benefits of providing human milk to very preterm (gestational
age (GA) < 32 weeks) or very low birth weight (VLBW, i.e., birth weight < 1500 g) infants have been
increasingly recognized [1–5]. Official bodies such as the World Health Organisation [6], American
Academy of Paediatrics [7], or the European Society for Paediatric Gastroenterology, Hepatology,
and Nutrition [8] recommend mother’s own milk (MOM) as the first choice in VLBW infant feeding
and advocate for making strong efforts to promote lactation. When MOM is not available, pasteurized
donor human milk (DHM) is the preferred choice [7,8]. When MOM and DHM are not available,
preterm formula (PF) should be used [8].
Although evidence exists regarding the protective effects of MOM in reducing the risk of
necrotizing enterocolitis (NEC), late-onset sepsis (LOS), and retinopathy of prematurity (ROP) in
VLBW infants, questions remain regarding whether DHM provides the same benefits [5,9–15]. DHM is
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usually donated by mothers of term infants and is pasteurized. Therefore, numerous MOM components
which could contribute to protect against adverse outcomes of prematurity are reduced or absent in
DHM [15–17].
Bronchopulmonary dysplasia (BPD) is the most common complication of extreme preterm birth.
Infants who develop BPD manifest aberrant or arrested pulmonary development and can experience
lifelong alterations in cardiopulmonary function [18,19]. Optimal nutritional support is considered
a cornerstone in the treatment/prevention of BPD [18,20]. Several studies have reported protective
effects of DHM in the development of BPD [10,21]. However, a systematic review of the evidence in
the literature has not been performed to date. Therefore, we aimed to conduct a systematic review
and meta-analysis of the interventional and observational studies reporting data on the effects of
pasteurized DHM on BPD as well as other indicators of pulmonary outcome in preterm infants.
2. Materials and Methods
A protocol was developed prospectively that detailed the specific objectives, criteria for study
selection, the approach to assessing study quality, clinical outcomes, and statistical methodology.
The study was carried out and reported according to the guidelines of the Preferred Reporting Items
for Systematic Reviews and Meta-Analysis (PRISMA) [22]. The PRISMA checklist for this report can
be found in supplementary material (Table S1).
2.1. Data Sources and Search Strategies
A comprehensive literature search was conducted using PubMed/MEDLINE and EMBASE,
from their inception to 1 December 2017. The search strategy for PubMed used the following
terms, including Mesh terms: (breast milk OR infant feeding OR donor milk OR pasteurized human
milk OR preterm formula) AND (preterm infant OR very low birth weight infant) AND (outcome
OR bronchopulmonary dysplasia OR BPD). A similar strategy was used in the other databases.
No language limit was applied. Translation was performed where necessary. Randomized controlled
trials (RCTs) and observational studies were included in the review. Narrative reviews, systematic
reviews, case reports, letters, editorials, and commentaries were excluded, but read to identify potential
additional studies. Additional strategies to identify studies included use of “related articles” feature
on PubMed, and use of “cited by” tool in Web of Science and Google Scholar.
2.2. Eligibility Criteria and Study Selection
Studies were included if they were RCTs, cohort studies or case-control studies, involving the
use of DHM in very preterm (GA < 32 weeks) or VLBW (BW < 1500 g) infants, included a study and
control group divided according to feeding policy, and reported results on BPD, days of mechanical
ventilation (MV) or days on oxygen (O2). BPD was defined as oxygen dependency at 28 days (BPD28)
or as oxygen dependency at 36 weeks post-menstrual age (BPD36). To identify relevant studies, two
reviewers (E.V.-M., E.V.) independently screened the results of the searches and applied inclusion
criteria using a structured form. Discrepancies were identified and resolved through discussion or in
consultation with the other researchers.
2.3. Data Extraction and Assessment of Risk of Bias
Two investigators (E.V.-M., E.V.) extracted the data by using a data collection form designed
for this review. The following information was collected: study type, number of patients,
number and name of centres, study period, inclusion/exclusion criteria, patient characteristics
(GA, BW), feeding intervention or observation (MOM, DHM, and/or PF, type of fortifier, duration
of intervention/observation), and outcome (incidence of BPD, days on mechanical ventilation,
days on oxygen). Two other investigators (M.P., G.C.) independently validated the accuracy of
the extracted data.
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Two reviewers (E.V.-M., E.V.) independently assessed risk of bias in each study, using two
predetermined tools. Risk of bias in RCTs was assessed by using the Cochrane “Risk of Bias
Assessment Tool” [23]. For each domain (random number generation, allocation concealment,
blinding of intervention and outcome assessors, completeness of follow-up, selectivity of reporting,
and other potential sources of bias) the risk was assessed as low, high, or unclear. Risk of bias in
observational studies was assessed using the Newcastle-Ottawa scale for quality assessment of cohort
and case-control studies [24]. This scale uses a rating system (range: 0–9) that gives points for selection
(0–4), comparability (0–2), and outcome/exposure (0–3). Discrepancies during the data extraction and
assessment of the risk of bias process were resolved by discussion and consensus among all reviewers.
2.4. Statistical Analysis
Studies were combined and analysed using comprehensive meta-analysis V 3.0 software
(Biostat Inc., Englewood, NJ, USA). For dichotomous outcomes, the Mantel-Haenszel (MH) risk
ratio (RR) with a 95% confidence interval (CI) was calculated from the data provided in the studies. For
continuous outcomes, the mean difference (MD) with 95% CI was calculated. When studies reported
continuous variables as median and range or interquartile range, we asked authors for mean and
standard deviation (SD). If they did not provide the requested data, we estimated the mean and SD
using the method of Wan et al. [25].
Due to anticipated heterogeneity, summary statistics were calculated with a random-effects model.
This model accounts for variability between studies as well as within studies. Subgroup analyses were
conducted according to the mixed-effects model [26]. In this model, a random-effects model is used to
combine studies within each subgroup and a fixed-effect model is used to combine subgroups and
yield the overall effect. The study-to-study variance (tau-squared) is not assumed to be the same for all
subgroups. This value is computed within subgroups and not pooled across subgroups. Statistical
heterogeneity was assessed by Cochran’s Q statistic and by the I2 statistic, which is derived from Q and
describes the proportion of total variation that is due to heterogeneity beyond chance [27]. We used
the Egger’s regression test and funnel plots to assess publication bias. A probability value of less than
0.05 (0.10 for heterogeneity) was considered statistically significant.
3. Results
Based on the titles and abstracts of 1081 citations, we identified 139 potentially relevant studies
(Figure 1), 18 of which met the inclusion criteria [10,21,28–43]. Seven studies [10,30,31,38,40,41,43] were
RCTs and 11 studies [21,28,29,32–37,39,42] were observational. The main characteristics of the included
RCTs are shown in Table 1, and the main characteristics of the included observational studies are shown
in Table 2. Definitions of feeding type varied across studies. None of the studies had BPD as their
primary outcome. To pool data, we classified feeding type comparisons into four categories: (1) DHM
vs. PF; (2) MOM vs. DHM; (3) raw MOM vs. pasteurized MOM; and (4) raw MOM vs. frozen MOM.
3.1. Quality Assessment and Publication Bias
Six of the seven RCTs [10,30,31,40,41,43] included in the review scored low risk of bias for random
sequence generation, allocation concealment, incomplete outcome data, selective reporting and other
bias (Table A1). Four studies [10,31,38,40] scored high or unknown risk of bias on blinding (Table A1).
The 12 observational studies included scored between 6 and 9 points on the Newcastle-Ottawa scale,
out of a possible 9 points (Table A2). The median score of included studies was 7 points.
We found no evidence of publication bias in any of the analyses that we performed, either through
visual inspection of funnel plots or Egger’s regression intercept. However, the limited amount of
studies per outcome makes these tests inconclusive.
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Table 1. Synoptic table of characteristics of included randomized controlled trials.
Authors n of Infants(Centers) Inclusion Criteria Primary Outcome(s)
Respiratory
Outcome(s)
Studied
Intervention
Duration of
Intervention Fortification Comments
Corpeleijn et al.
2016 [30] 373 (6)
BW <1500 g, MOM
insufficiently available.
Composite incidence of
NEC, serious infection
(sepsis or meningitis), or
all-cause mortality between
72 h and 60 days of life.
BPD28 - MOM + DHM- MOM + PF
10 days or hospital
transfer or death.
Bovine fortifier
added to MOM
and DHM.
Median MOM intakes
were higher in the
DHM group, 89.1% in
the DHM group vs.
84.5% in the PF group.
Cossey et al.
2013 [31] 303 (1)
GA <32 weeks,
BW < 1500 g.
Incidence of proven
late-onset sepsis. BPD36, days on MV
- Raw MOM + PF
- Pasteurized MOM
+ PF
Eight weeks or
discharge. Not specified.
MV defined as
respiratory support.
Cristofalo et al.
2013 [43] 53 (7)
BW 500–1250 g, no
intention to provide
MOM, parenteral
nutrition within 48 h,
enteral feeding within
21 days.
Duration of parenteral
nutrition.
Days on MV, days
on O2
- Exclusive DHM
- Exclusive PF
91 days of age or
discharge, or
attainment of 50%
oral feedings.
DHM fortifier added
to DHM.
O’Connor et al.
2016 [41] 363 (4)
BW < 1500 g, enteral
feeding within 7 days.
Bayley-III score at
18 months. BPD36
- MOM + DHM
- MOM + PF 90 days or discharge.
Bovine fortifier
added to MOM
and DHM.
MOM + DHM group:
MOM = 58% of intake.
MOM + PF group:
MOM = 63% of intake.
Omarsdottir et al.
2015 [38] 140 (2)
GA < 28 weeks,
intention to provide
MOM, intention to
breastfeed.
CMV transmission to
infants from breast milk,
rate of symptomatic CMV
infection.
BPD36
- Frozen MOM +
DHM
- Fresh MOM +
frozen MOM +
DHM
Until 32 weeks
PMA. Not specified.
Frozen MOM: stored
for ≥3 days at −20 ◦C.
Fresh MOM: fed
immediately or after
refrigeration at +4 ◦C.
Schanler et al.
2005 [10] 243 (1) GA ≤ 29 weeks.
Incidence of late-onset
sepsis and/or NEC. BPD36, days on MV
- MOM + DHM
- MOM + PF 90 days or discharge.
Bovine fortifier
added to MOM
and DHM.
Sullivan et al.
2010 [40] 207 (12)
BW 500–1250 g,
intention to
provide MOM.
NEC. BPD36, days on MV,days on O2
- MOM + DHM +
DHM fortifier
- MOM + PF +
bovine fortifier
91 days or ≥50%
oral feedings
or discharge.
Donor DHM-based
fortifier in DHM
group, bovine
fortifier in PF group.
BPD28: bronchopulmonary dysplasia, defined as oxygen dependency at day 28 of life; BPD36: bronchopulmonary dysplasia, defined as oxygen dependency at 36 weeks corrected
gestational age; MOM: mother’s own milk; PF: preterm formula; DHM: donor human milk; MV: mechanical ventilation; GA: gestational age; BW: birth weight; PMA: post-menstrual age;
CMV: Cytomegalovirus; NEC: necrotizing enterocolitis.
Nutrients 2018, 10, 238 5 of 16
Table 2. Synoptic table of characteristics of included observational studies.
Authors Study Design n of Infants(Centers) Inclusion Criteria Primary Outcome(s) Respiratory Outcome(s) Groups Duration of Intervention Fortification Comments
Assad et al.
2015 [28] Retrospective cohort 293 (1)
GA < 29 and/or BW ≤ 1500
g.
Feeding intolerance, time
to full feeds, length of
stay.
BPD36
- MOM + DHM +
DHM-based fortifier; - MOM
+ bovine fortifier; - MOM +
PF + bovine fortifier; -
Exclusive PF
Until discharge.
DHM fortifier in
exclusive human diet,
bovine fortifier in bovine
groups.
Colacci et al.
2017 [29] Retrospective cohort 85 (1) BW < 1000 g, GA < 37 weeks.
Neurodevelopmental
impairment (Bayley-III
score).
BPD36
- MOM + DHM +
DHM-based fortifier; - MOM
+ PF + bovine fortifier
At least four weeks, until
weight ≥ 1500 g, or 34 weeks
PMA.
DHM-based fortifier in
exclusive human milk
group, bovine fortifier in
other group.
Dicky et al.
2017 [32] Retrospective cohort 926 (63)
GA < 32 weeks, alive at 7
days of life.
In-hospital mortality,
short-term morbidity,
weight gain.
BPD36, Days on MV,
Days on oxygen
- Raw MOM + PF/DHM;
- Pasteurized MOM +
PF/DHM
Until 33 weeks corrected age
or until discharge.
Bovine fortifier added to
both groups.
The supplement (PF, DHM,
infant formula) to raw or
pasteurized MOM varied per
center.
Ginovart et al.
2016 [33] Retrospective cohort 186 (1) BW < 1500 g.
Retinopathy of
prematurity.
BPD28, BPD36, days on
MV, days on O2
- MOM + DHM; - MOM + PF Four weeks. Bovine fortifier added toMOM and to DHM.
Additional data provided by
authors, and from later
(2017) report of
Ginovart et al. [44].
Giuliani et al.
2012 [34] Retrospective cohort 92 (1) GA > 23 weeks, BW < 1500 g.
Growth, and short-term
clinical outcomes. BPD28
- Mainly MOM (>80%);
- Mainly DHM (>80%) 32 weeks corrected GA.
Bovine fortifier added to
MOM.
Hair et al.
2016 [35] Retrospective cohort 1587 (4) BW < 1250 g. NEC, mortality. BPD36, days on MV
- MOM + DHM +
DHM-based fortifier; - MOM
+ PF + bovine fortifier
32–34 corrected GA,
or 60 days of life. depending
on the centre.
DHM-based fortifier in
DHM group.
Bovine fortifier in bovine
group.
Kreissl et al.
2017 [36] Prospective cohort 283 (1) GA < 32 weeks, BW < 1500 g.
Time to full enteral
feeding. BPD36 - MOM + DHM; - MOM + PF
Until term or discharge.
DHM group received DHM
until MOM was available or
until reaching
140 mL/kg/day, then
switched to term formula.
Bovine fortifier added to
MOM and DHM when
infant reached intake of
100 mL/kg/day.
DHM provided by other
preterm mothers.
Lee et al.
2016 [37] Retrospective cohort 46 (1) BW < 1500 g.
Morbidity, duration
parenteral nutrition,
length of hospital stay.
BPD36, days on MV, days
on O2
- MOM + DHM; - MOM + PF Not specified. Not specified.
Days on MV: defined as
invasive ventilation. Days
on O2 defined as
non-invasive ventilation.
Madore et al.
2017 [42]
Retrospective
case-control 81 (1) BW < 1000 g.
Growth,
neurodevelopment. BPD36
- Exclusive MOM; -
DHM > 50%; - PF > 50% First month of life.
Bovine fortifier added to
MOM and to DHM.
Sisk et al.
2017 [39] Retrospective cohort 563 (1)
GA ≤ 32 weeks and
BW ≤ 1500 g. NEC stage ≥ 2. BPD36
- MOM ≥ 50%; -
DHM ≥ 50%; - PF ≥ 50%
Within 2 h of birth until
34 weeks PMA.
Bovine fortifier added to
MOM and to DHM.
Spiegler et al.
2016 [21] Prospective cohort 1433 (48) GA 22–31 6/7, BW < 1500 g. BPD.
BPD36, days on MV, days
on O2
- MOM + DHM; - MOM +
DHM + PF; - Exclusive PF Until discharge.
Bovine fortifier added to
MOM and to DHM.
BPD: bronchopulmonary dysplasia; BPD28: bronchopulmonary dysplasia defined as oxygen dependency after day 28 of life. BPD36: bronchopulmonary dysplasia, defined as oxygen
dependency at 36 weeks corrected gestational age; MV: mechanical ventilation; MOM: mother’s own milk; PF: preterm formula; DHM: donor human milk; GA: gestational age; BW: birth
weight. PMA: post-menstrual age. NEC: necrotizing enterocolitis.
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Figure 1. Flow diagram of the literature search process.
3.2. Randomized Controlled Trials: Donor Human Milk vs. Preterm Formula
Five RCTs [10,30,40,41,43] randomized infants to receive DHM or PF when MOM was
insufficiently available. Thus, they compared infants receiving MOM supplemented with DHM
vs. infants receiving MOM supplemented with PF. Three of these studies [10,40,41] reported on the
rate of BPD36. As shown in Figure 2, meta-analysis could not detect a statistically significant effect of
DHM on BPD36 (RR 0.89, 95% CI 0.60 to 1.32, p = 0.562). The RCT of Sullivan et al. used a DHM-based
fortifier in the DHM group, and a bovine milk-based fortifier in the PF group. The studies of Schanler
et al. [10] and O’Connor et al. [41] used a bovine milk-based fortifier in both groups. Exclusion of the
study of Sullivan et al. [40] for using a different type of fortifier did not significantly affect the results
of the meta-analysis on BPD36 (RR 0.85, 95% CI 0.39 to 1.85, p = 0.676). One study [30] reported on
BPD28 and could not find any significant effect (RR 1.06, 95% CI 0.75 to 1.51, p = 0.724).
Nutrients 2018, 10, 238 7 of 16
Nutrients 2018, 10, x FOR PEER REVIEW  7 of 16 
 
 
Figure 2. Meta-analysis of randomized controlled trials assessing the effects of supplementation of 
MOM with DHM, compared with supplementation with PF, on risk of BPD36. Circles (O) represent 
the effect sizes per study, and their size represents the relative weight of the study in the meta-
analysis. Diamonds (◆) represent the pooled effect size. DHM: donor human milk; PF: preterm 
formula; BPD36: bronchopulmonary dysplasia defined as oxygen dependency at 36 weeks post-
menstrual age; MH: Mantel-Haenszel. 
Three studies [10,40,43] reported data on days on mechanical ventilation, and meta-analysis 
showed a significant reduction in this outcome for infants receiving DHM (MD −5.73 days, 95% CI 
−10.68 to −0.77, p = 0.023, Figure 3). Two studies [40,43] reported data on days on oxygen, and meta-
analysis could not find a significant reduction in this outcome for infants receiving DHM (MD −9.11 
days, 95% CI −24.82 to 6.60, p = 0.256). 
 
Figure 3. Meta-analysis of randomized controlled trials assessing the effects of supplementation of 
MOM with DHM, compared with supplementation with PF, on mean days on MV. Circles (O) 
represent the effect sizes per study, and their size represents the relative weight of the study in the 
meta-analysis. Diamonds (◆) represent the pooled effect size. DHM: donor human milk; PF: preterm 
formula; MV: mechanical ventilation. 
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Three studies [10,40,43] reported data on days on mechanical ventilation, and meta-analysis
showed a significant reduction in this outcome for infants receiving DH ( D −5.73 days, 95% CI
−10.68 to −0.77, p = 0.023, Figure 3). Two studies [40,43] reported data on days on oxygen, and
meta-analysis could not find a significant reduction in this outcome for infants receiving DHM
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a significant protective effect of DHM on BPD36 (RR 0.80, 95% CI 0.68 to 0.95, p = 0.009, Figure 4).
This protective effect of DHM on BPD36 was also observed when the five studies [21,33,36,37,39] that
did not use DHM-based ortifie were pooled (RR 0.71, 95% CI 0.53 to 0.95, p = 0.022, Figure 4) and
when he 8 studies were combined in a mixed-effects meta-analysis (RR 0.78, 95% CI 0.67 to 0.89
p = 0.0005, Figure 4). The study of Ginovart et al. [33] also rep rted data o BPD28 and found no
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significant difference in this outcome between the group receiving DHM and the group receiving PF
(RR 1.18, 95% CI 0.68 to 2.05, p = 0.560).
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Four studies [21,33,35,37] reported data on mean days on mechanical ventilation, and
meta-analysis showed a significant reduction in difference in means in the DHM-group (MD 2.14 days,
95% CI −4.08 to −0.21, p = 0.030, Figure 5). Three studies [21,33,37] reported data mean on days on
oxygen, and meta-analysis could not find a significant difference in mean days on oxygen in the DHM
group (MD −2.78 days, 95% CI −6.32 to 0.76, p = 0.123, Figure 6).
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3.4. Mother’s Own Milk vs. Donor Human Milk
Five observational studies [10,28,34,39,42] compared infants who received mainly MOM
vs. infants who received mainly DHM. There were significant differences in group design.
Giuliani et al. [34] compared infants receiving >80% MOM (supplemented with <20% DHM) vs. infants
receiving <20% MOM (supplemented with >80% DHM). Sisk et al. [39] and Madore et al. [42] compared
infants receiving ≥50% MOM to infants receiving ≥50% DHM. The RCT of Schanler et al. [10]
randomized infants to receive either DHM or PF as supplementation when insufficient MOM was
available, but also provided data on infants who only received MOM. We treated it as observational for
this comparison, and compared infants who received exclusive MOM to infants who received MOM
supplemented with DHM.
Four of the five studies reported on BPD36, and meta-analysis could not find a significant
difference in BPD36 risk in the MOM-group compared to the DHM-group (RR 1.24, 95% CI 0.87 to 1.77,
p = 0.231, Figure 7). The study of Giuliani et al. [34] reported on BPD28 and did not find any significant
effect of MOM on this outcome (RR 0.91, 95% CI 0.43 to 1.93, p = 0.804).
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in BPD36 risk in the raw MOM group when using unadjusted data (Figure 8), although Dicky et al.
found a significant reduction on BPD36 risk in the raw MOM group when they adjusted their data
for confounders (adjusted OR 0.40, 95% CI 0.27 to 0.67, p < 0.001). Since the study of Dicky et al.
had a quasi-randomized design, we combined it with the RCT of Cossey et al. in a random effects
meta-analysis. This analysis showed a significant reduction of BPD36 risk in the raw MOM group
(RR 0.77, 95% CI 0.62 to 0.96, p = 0.018, Figure 8).
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and supplementation with either DHM or PF varied across studies. Fourth, there was substantial
heterogeneity among the studies in population, timing of initiation, and duration of the intervention.
Fifth, the definitions of days on mechanical ventilation and days on oxygen were heterogenous and
frequently unclear, and the data itself were not always normally distributed. An additional limitation,
inherent to any meta-analysis on BPD, is the heterogeneity of the definition of the condition [46–49].
Finally, many studies were observational, which potentially reduced the reliability of the results.
Despite all these limitations, our meta-analysis shows an additional benefit of using DHM instead of
PF in VLBW infants.
Out of 18 studies we included in our analysis, 12 were published in 2016 or 2017. The use of DHM
in the NICU is a topic of much discussion, and the recency of most studies we included reflects this.
As more centres start using DHM in clinical practice, and as more RCTs and observational studies are
reported, the results of our meta-analyses could change or be confirmed further.
There are several hypothetical mechanisms by which human milk may exert a protective effect
against BPD: (i) by improving the nutritional status and growth of the infants; (ii) by reducing
postnatal inflammatory processes, such as NEC and LOS; (iii) by modulating the immune functions;
and (iv) through the antioxidant properties of human milk. However, the term human milk feeding is
frequently used to encompass both MOM and DHM, implying that the multiple beneficial outcomes
attributed to MOM can be generalized to DHM [14,15]. This assumption may not be correct because
of the important differences between DHM and MOM. As discussed below, part of these differences
may be attributed to pasteurization, but there are additional factors that could play a role in the
development of outcomes, such as BPD. DHM is typically donated by women who have delivered
a term infant and this milk has different levels of nutrients and protective components, including
cytokines, growth factors, and lactoferrin, than the milk provided by a mother for her own preterm
infant [14,15]. Moreover, it has been suggested that the beneficial effects of MOM may be unique
to the specific mother-infant dyad, thereby providing maximum protection to the mother’s own
infant [14,15].
The concern about transmission of infectious agents through breast milk led to the obligatory
requirement for pasteurization of DHM. Holder pasteurization (62.5 ◦C for 30 min) of DHM is
performed in order to inactivate the microbial agents that may be present [50]. However, pasteurization
also destroys or significantly decreases many of the protective elements in human milk, including,
among others, lysozymes, secretory immunoglobulin A, growth factors, lactoferrin, antioxidants, and
commensal bacteria [14,15,50–52]. Although numerous studies have characterized the effects of Holder
pasteurization on the biological properties of DHM (see [50] for review), the impact of pasteurization
on clinical outcomes has been scarcely investigated. Since DHM should always be pasteurized, it is
ethically impossible to study the clinical impact of unpasteurized DHM. However, there are studies
comparing pasteurized to unpasteurized MOM. The main purpose of this pasteurization of MOM is
the prevention of cytomegalovirus (CMV) infection [53].
We included two studies in our systematic review that reported the clinical outcomes of VLBW
infants receiving unpasteurized or pasteurized MOM. The study of Cossey et al. [31] was a single-centre
RCT, whereas the study of Dicky et al. [32] compared infants from 33 French NICUs that used
pasteurized MOM to infants from 30 French NICUs that did not pasteurize MOM. Due to the
quasi-randomized design of the study of Dicky et al., we combined it with the study of Cossey
et al. in a meta-analysis, which showed that infants fed pasteurized MOM had a significantly higher
risk of BPD than infants fed raw MOM (see Figure 8). Therefore, our data suggest that the possible
protective effect of human milk on BPD decreases with pasteurization.
As mentioned above, Holder pasteurization not only inactivates all common pathogens in human
milk but also affects the commensal microbiota [50]. The microbiota of breast milk has been associated
with many of the benefits of raw MOM [54], namely with respect to the prevention of NEC [55,56].
The beneficial effects on the prevention of NEC could not be repeated with pasteurized DHM [30],
which may be due to the loss of the microbiota [56,57]. The microbiota of breast milk can be “regrown”
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in pasteurized DHM with the inoculation of unprocessed MOM [58] which awaits clinical testing.
BPD has also been associated with changes in the microbiota of the airways [59,60] and may even be
associated with the gut microbiota [61]. Unfortunately, we have no complete understanding about the
origin, dynamics and biological function of the respiratory microbiome [62]. Nevertheless, the effect of
MOM’s microbiota on the infant gut microbiota and possibly the infant respiratory microbiota may
explain our finding on the loss of beneficial effects after pasteurization of human milk.
In some NICUs, MOM is routinely frozen to reduce the risk of CMV transmission [53]. In our
systematic review we included one RCT [38] which studied the effect of freezing MOM compared to
providing fresh MOM. They found a close to significant increased risk of BPD in the group receiving
fresh MOM (RR 1.47, 95% CI 0.98 to 2.21, p = 0.062). It is worth noting that this study was not powered
to detect differences in BPD. Further studies are needed to elucidate the effect of MOM-freezing on
neonatal outcomes.
Both MOM and DHM must be fortified to provide sufficient support for growth and development
in the postnatal period of the VLBW infant [63–66]. At present, most NICUs use bovine milk-derived
fortifiers. However, the recent availability of a DHM-derived fortifier has led to the introduction of the
concept of “exclusive human milk diet” [28,29,35,40]. This diet consists of MOM, DHM if MOM is not
adequately available, and fortification with DHM-derived fortifier. Our data suggest that this exclusive
human milk diet may reduce the risk of developing BPD. However, this result should be interpreted
with care. Most studies evaluating the use of an exclusive human milk diet [29,35,40] do not isolate
the individual effects of the DHM-derived fortifier, because the group receiving bovine products is a
mixture of infants fed DHM plus bovine milk-derived fortifier and infants fed PF. Therefore, it is not
possible to determine whether the lower risk of BPD was due to the benefit of DHM-derived fortifier or
to the benefit of avoiding PF. Only the study of Assad et al. [28] provided data on infants not exposed
to PF and could not find a significant change in BPD risk when using DHM-derived fortifier, compared
to bovine-derived fortifier.
Maintaining a sufficient (unpasteurized) MOM supply is challenging for mothers of VLBW infants,
necessitating supplementation with either DHM or PF. Our results suggest the superiority of DHM
over PF in reducing BPD, but we should not forget that MOM is more effective in the reduction of
multiple morbidities and is less expensive to acquire than DHM. Therefore, NICU care providers
should prioritize interventions to support initiation and maintenance of lactation and make efforts to
identify and solve lactation problems in mothers of VLBW infants.
Supplementary Materials: The following are available online at www.mdpi.com/2072-6643/10/2/238/s1,
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Appendix A
Table A1. Assessment of risk of bias of included randomized controlled trials.
Study
Random
Sequence
Generation
Allocation
Concealment
Blinding of
Participants
and Personnel
Blinding of
Outcome
Assessment
Incomplete
Outcome
Data
Selective
Reporting
Other
Bias
Corpeleijn et al. 2016 [30] LR LR LR LR LR LR LR
Cossey et al. 2013 [31] LR LR HR UR LR LR LR
Cristofalo et al. 2013 [43] LR LR LR LR LR LR LR
O’Connor et al. 2016 [41] LR LR LR LR LR LR LR
Omarsdottir et al. 2015 [38] UR UR HR UR LR LR LR
Schanler et al. 2005 [10] LR LR HR HR LR LR LR
Sullivan et al. 2010 [40] LR LR HR LR LR LR LR
LR: low risk of bias, HR: high risk of bias, UR: unknown risk of bias.
Table A2. Assessment of methodological quality of included observational studies, using the
Newcastle-Ottawa Scale.
Study Name Study Design Selection (0–4 Points) Comparability (0–2) Outcome (0–3) Total (0–9)
Assad et al. 2015 [28] Retrospective cohort 4 0 3 7
Colacci et al. 2017 [29] Retrospective cohort 4 0 3 7
Dicky et al. 2017 [32] Retrospective cohort 4 2 3 9
Ginovart et al. 2016 [33] Retrospective cohort 4 0 3 7
Giuliani et al. 2012 [34] Retrospective case-control 4 0 3 7
Hair et al. 2016 [35] Retrospective cohort 4 0 3 7
Kreissl et al. 2017 [36] Prospective cohort 4 0 3 7
Lee et al. 2016 [37] Retrospective cohort 4 0 2 6
Madore et al. 2017 [42] Retrospective case-control 4 2 3 9
Sisk et al. 2017 [39] Retrospective cohort 4 0 3 7
Spiegler et al. 2016 [21] Prospective cohort 4 2 3 9
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